Galmed Pharma (GLMD)
0.50
-0.02 (3.85%)
Upcoming Events
Latest Headlines
Form 6-K Galmed Pharmaceuticals For: Jul 22
July 22, 2026 4:15 PM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Jul 16
July 16, 2026 7:43 AM - SEC Filing
Galmed develops heart-targeted nanoparticle formulation of Aramchol
July 16, 2026 7:32 AM - StreetInsider
Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
July 16, 2026 7:30 AM - PR NewsWire
Form 6-K Galmed Pharmaceuticals For: Jul 08
July 8, 2026 4:15 PM - SEC Filing
Core AI Holdings names Arie Goor as CFO, effective July 1
July 7, 2026 8:20 AM - StreetInsider
Imunon names new interim CFO as predecessor retires
June 30, 2026 4:40 PM - StreetInsider
Form 424B3 Galmed Pharmaceuticals
June 22, 2026 7:05 AM - SEC Filing
Galmed completes Colospan acquisition under restructured terms
June 22, 2026 7:02 AM - StreetInsider
Form 6-K Galmed Pharmaceuticals For: Jun 22
June 22, 2026 7:00 AM - SEC Filing
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
June 22, 2026 7:00 AM - PR NewsWire
Form POS EX Galmed Pharmaceuticals
June 8, 2026 8:36 AM - SEC Filing
Form 424B3 Galmed Pharmaceuticals
June 8, 2026 8:33 AM - SEC Filing
Form 6-K Galmed Pharmaceuticals For: Jun 08
June 8, 2026 8:26 AM - SEC Filing
Galmed to acquire Colospan for $4.5 million in medical device deal
June 8, 2026 8:11 AM - StreetInsider
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
June 8, 2026 8:11 AM - PR NewsWire
Form 6-K Galmed Pharmaceuticals For: Jun 02
June 2, 2026 7:58 AM - SEC Filing
Galmed and Tissue Dynamics identify cardiac fibrosis pathway
June 2, 2026 7:31 AM - StreetInsider
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
June 2, 2026 7:30 AM - PR NewsWire
Form 6-K Galmed Pharmaceuticals For: May 14
May 14, 2026 7:52 AM - SEC Filing
Galmed reports 500% bioavailability boost for oral aramchol formulation
May 14, 2026 7:31 AM - StreetInsider
Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 3
May 14, 2026 7:30 AM - PR NewsWire
Form 6-K Galmed Pharmaceuticals For: May 06
May 6, 2026 7:47 AM - SEC Filing
Tissue Dynamics partners with Galmed to develop cardiac fibrosis platform
May 6, 2026 7:32 AM - StreetInsider
Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
May 6, 2026 7:30 AM - PR NewsWire
Full Article List
